Search Result

Results for "

ovarian carcinomas

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Antibiotic (1) Apoptosis (17) Autophagy (10) Bacterial (2) Bcl-2 Family (2) Caspase (1) Cytochrome P450 (2) DNA Alkylator/Crosslinker (4) E1/E2/E3 Enzyme (2) FAK (1) Ferroptosis (5) FXR (1) HDAC (1) Histone Demethylase (1) IAP (1) Isotope-Labeled Compounds (3) LXR (1) Macrophage migration inhibitory factor (MIF) (1) MDM-2/p53 (2) MEK (1) Microtubule/Tubulin (1) MMP (1) Molecular Glues (1) Monoamine Oxidase (2) NF-κB (1) P-glycoprotein (2) P2X Receptor (2) Parasite (1) PARP (3) PPAR (5) Raf (1) RAR/RXR (1) Reverse Transcriptase (2) ROR (1) Survivin (2) TAM Receptor (1) Toll-like Receptor (TLR) (2) Topoisomerase (1) TRP Channel (5) Wee1 (1)
By Research Areas:	Cancer (37) Cardiovascular Disease (2) Infection (3) Inflammation/Immunology (12) Metabolic Disease (6) Neurological Disease (7)

By Targets:

ADC Cytotoxin (1)

Antibiotic (1)

Apoptosis (17)

Autophagy (10)

Bacterial (2)

Bcl-2 Family (2)

Caspase (1)

Cytochrome P450 (2)

DNA Alkylator/Crosslinker (4)

E1/E2/E3 Enzyme (2)

FAK (1)

Ferroptosis (5)

FXR (1)

HDAC (1)

Histone Demethylase (1)

IAP (1)

Isotope-Labeled Compounds (3)

LXR (1)

Macrophage migration inhibitory factor (MIF) (1)

MDM-2/p53 (2)

MEK (1)

Microtubule/Tubulin (1)

MMP (1)

Molecular Glues (1)

Monoamine Oxidase (2)

NF-κB (1)

P-glycoprotein (2)

P2X Receptor (2)

Parasite (1)

PARP (3)

PPAR (5)

Raf (1)

RAR/RXR (1)

Reverse Transcriptase (2)

ROR (1)

Survivin (2)

TAM Receptor (1)

Toll-like Receptor (TLR) (2)

Topoisomerase (1)

TRP Channel (5)

Wee1 (1)

By Research Areas:

Cancer (37)

Cardiovascular Disease (2)

Infection (3)

Inflammation/Immunology (12)

Metabolic Disease (6)

Neurological Disease (7)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99262

Imalumab BAX69; Anti-Human MIF Recombinant Antibody	Macrophage migration inhibitory factor (MIF)	Cancer
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .

HY-10029

Nutlin-3a 40+ Cited Publications Rebemadlin	MDM-2/p53 E1/E2/E3 Enzyme Autophagy Apoptosis	Cancer
Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC₅₀=90 nM). Nutlin-3a inhibits MDM2-p53?interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53?wild-type ovarian carcinomas .

HY-N10535

Lewis y tetrasaccharide Lewis y	FAK	Cancer
Lewis Y tetrasaccharide (Lewis Y, Le ^Y) is a tetrasaccharide derivative form of Lewis X trisaccharide (HY-N10534). Lewis Y tetrasaccharide is an antigen associated with malignant ovarian carcinomas metastasis and poor prognosis .

HY-139782

SKLB325	Histone Demethylase Apoptosis	Cancer
SKLB325 is a Jumonji domain-containing 6 (JMJD6) inhibitor with a binding affinity (K_D) value of 0.755?μM, and the IC₅₀ value of 0.7797?μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis . SKLB325 exhibits remarkable antitumor efficacy in renal cell carcinoma (RCC) .

HY-125593

Dasminapant APG-1387	IAP Apoptosis	Cancer
Dasminapant (APG-1387), a bivalent SMAC mimetic and an IAP antagonist, blocks the activity of IAPs family proteins (XIAP, cIAP-1, cIAP-2, and ML-IAP). Dasminapant induces degradation of cIAP-1 and XIAP proteins, as well as caspase-3 activation and PARP cleavage, which leads to apoptosis. Dasminapant can be used for the research of hepatocellular carcinoma, ovarian cancer, and nasopharyngeal carcinoma .

HY-N0462

Corilagin 4 Publications Verification	Toll-like Receptor (TLR) Reverse Transcriptase Bacterial Apoptosis Autophagy	Infection Inflammation/Immunology Cancer
Corilagin, a gallotannin, has anti-tumor, anti-inflammatory and hepatoprotective activities. Corilagin inhibits activity of reverse transcriptase of RNA tumor viruses. Corilagin also inhibits the growth of Staphylococcus aureus with a MIC of 25 μg/mL. Corilagin shows anti-tumor activity on hepatocellular carcinoma and ovarian cancer model. Corilagin shows low toxicity to normal cells and tissues .

HY-P99463

Batiraxcept AVB-S6-500	TAM Receptor	Cancer
Batiraxcept (AVB-S6-500) is a highly potent and specific AXL inhibitor, a recombinant fusion protein dimer containing the extracellular domain of human AXLM and human immunoglobulin G1 heavy chain (Fc). Batiraxcept binds to GAS6 and inhibits the interaction of GAS6 with AXL, thereby substantially reducing AXL signaled invasion and migration of highly metastatic cells in vitro and inhibiting metastatic disease in nonclinical models of aggressive human cancers. Batiraxcept is available for studies in advanced or metastatic clear cell renal cell carcinoma (ccRCC) and platinum sensitive recurrent ovarian cancer .

HY-161871

WEE1-IN-8	Wee1	Cancer
WEE1-IN-8 (Compound 55) is a selective WEE1 inhibitor, with an IC₅₀ of 0.98 nM. WEE1-IN-8 (Compound 55) can be used for the research of Pancreatic cancer, Ovarian cancer, Colorectal cancer, Uterine serous carcinoma, etc .

HY-N0462R

Corilagin (Standard)	Toll-like Receptor (TLR) Reverse Transcriptase Bacterial Apoptosis Autophagy	Infection Inflammation/Immunology Cancer
Corilagin (Standard) is the analytical standard of Corilagin. This product is intended for research and analytical applications. Corilagin, a gallotannin, has anti-tumor, anti-inflammatory and hepatoprotective activities. Corilagin inhibits activity of reverse transcriptase of RNA tumor viruses. Corilagin also inhibits the growth of Staphylococcus aureus with a MIC of 25 μg/mL. Corilagin shows anti-tumor activity on hepatocellular carcinoma and ovarian cancer model. Corilagin shows low toxicity to normal cells and tissues .

HY-162721

Anticancer agent 242	Others	Cancer
Anticancer agent 242 (7) possesses anticancer activity in A2780 (IC₅₀ = 0.24 μM, ovarian adenocarcinoma), A2780cis (IC₅₀ = 0.45 μM, resistant derivative of A2780), CCD18Co (IC₅₀ = 0.59 μM, non-malignant human fibroblasts), A549 (IC₅₀ = 0.32 μM, lung carcinoma), HT29 (IC₅₀ = 0.26 μM, colorectal adenocarcinoma), and MCF7 (IC₅₀ = 0.55 μM, breast adenocarcinoma) .

HY-130326

RAPTA-C Ru(η6-p-cymene)Cl2(pta)	Apoptosis Caspase	Cardiovascular Disease Cancer
RAPTA-C (Ru(η6-p-cymene)Cl2(pta)) acts as an anti-cancer and anti-angiogenic agent. RAPTA-C exhibits anti-metastatic, anti-angiogenic, and anti-tumoral activities through protein and histone-deoxyribonucleic acid alterations. RAPTA-C exhibits cell growth inhibition by triggering G(2)/M phase arrest in cancer cells. RAPTA-C also enhances the levels of p53 and triggers the mitochondrial Apoptotic pathway, resulting in cytochrome C release and caspase-9 activation. RAPTA-C reduces the growth of tumors with the inhibition of angiogenesis in a ovarian carcinoma model .

HY-107020

BMS 310705 21-Aminoepothilone B	Apoptosis	Cancer
BMS 310705 (21-Aminoepothilone B) is an analog of Epothilone B (HY-17029), targeting to malignancies such as ovarian, renal, bladder, and lung carcinoma. BMS 310705 induces significant apoptosis via mitochondrial-mediated pathway .

HY-14653

Amsilarotene TAC-101; Am 555S	RAR/RXR Apoptosis	Cancer
Amsilarotene (TAC-101; Am 555S), an orally active synthetic retinoid, has selective affinity for retinoic acid receptor α (RAR-α) binding with K_i of 2.4, 400 nM for RAR-α and RAR-β. Amsilarotene induces the apoptotic of human gastric cancer, hepatocellular carcinoma and ovarian carcinoma cells. Amsilarotene can be used for the research of cancer .

HY-B1311

Proadifen hydrochloride 1 Publications Verification SKF-525A; U-5446; RP-5171	Cytochrome P450 Monoamine Oxidase Bcl-2 Family Survivin PARP	Neurological Disease Inflammation/Immunology Cancer
Proadifen (SKF-525A) hydrochloride is a non-competitive Cytochrome P450 inhibitor with an IC₅₀ value of 19 μM. Proadifen hydrochloride reduces monoamine oxidase A (MAO-A) activity and reverses the antidepressantlike behavioral effect of Imipramine (HY-B1490A) and Desipramine (HY-B1272A) in rats. Proadifen hydrochloride also reduces N, N-dimethyltryptamine (DMT) metabolism in liver microsomes and inhibits N-demethylationand Acridone (HY-W007771) formation. Proadifen hydrochloride augments Lipopolysaccharide (LPS) (HY-D1056)-induced fever and exacerbates Prostaglandin E2 (PGE2) (HY-101952) levels in the rat. Proadifen hydrochloride is promising for research of metabolism-related deseases, ovarian carcinoma, inflammation and dopamine neurons-related deseases .

HY-13593

Chlorambucil 4 Publications Verification CB-1348; WR-139013	DNA Alkylator/Crosslinker	Cancer
Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease .

HY-B1311R

Proadifen hydrochloride (Standard)	Cytochrome P450 Monoamine Oxidase Bcl-2 Family Survivin PARP	Neurological Disease Inflammation/Immunology Cancer
Proadifen (hydrochloride) (Standard) is the analytical standard of Proadifen (hydrochloride). This product is intended for research and analytical applications. Proadifen (SKF-525A) hydrochloride is a non-competitive Cytochrome P450 inhibitor with an IC50 value of 19 μM. Proadifen hydrochloride reduces monoamine oxidase A (MAO-A) activity and reverses the antidepressantlike behavioral effect of Imipramine (HY-B1490A) and Desipramine (HY-B1272A) in rats. Proadifen hydrochloride also reduces N, N-dimethyltryptamine (DMT) metabolism in liver microsomes and inhibits N-demethylationand Acridone (HY-W007771) formation. Proadifen hydrochloride augments Lipopolysaccharide (LPS) (HY-D1056)-induced fever and exacerbates Prostaglandin E2 (PGE2) (HY-101952) levels in the rat. Proadifen hydrochloride is promising for research of metabolism-related deseases, ovarian carcinoma, inflammation and dopamine neurons-related deseases [4] .

HY-13593S

Chlorambucil-d8 CB-1348-d₈; WR-139013-d₈	Isotope-Labeled Compounds DNA Alkylator/Crosslinker	Cancer
Chlorambucil-d₈ is the deuterium labeled Chlorambucil. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease[1][2][3][4].

HY-13593S1

Chlorambucil-d8-1 CB-1348-d₈-1; WR-139013-d₈-1	Isotope-Labeled Compounds DNA Alkylator/Crosslinker	Cancer
Chlorambucil-d₈-1 is the deuterium labeled Chlorambucil. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease[1][2][3][4].

HY-13593R

Chlorambucil (Standard)	DNA Alkylator/Crosslinker	Cancer
Chlorambucil (Standard) is the analytical standard of Chlorambucil. This product is intended for research and analytical applications. Chlorambucil (CB-1348), an orally active antineoplastic agent, is a bifunctional alkylating agent belonging to the nitrogen mustard group. Chlorambucil can be used for the research of lymphocytic leukemia, ovarian and breast carcinomas, and Hodgkin’s disease .

HY-18652A

Avutometinib potassium Ro 5126766 potassium; CH5126766 potassium	Raf MEK	Cancer
Avutometinib (CH5126766) (potassium) is a RAF/MEK clamp that potently inhibits RAF/MEK kinase activity and induces dominant negative RAF-MEK complexes preventing phosphorylation of MEK by ARAF, BRAF and CRAF. Avutometinib (potassium) shows anti-proliferative potency across tumor cell lines carrying KRAS mutations including PDAC cell lines. Avutometinib (potassium) induces tumor inhibition and increases survival in a KRAS/p53 pancreatic cancer mouse model. Avutometinib (potassium) is promising for research of low-grade-serous-ovarian-carcinoma (LGSOC), ovarian cancer and pancreatic ductal adenocarcinoma (PDAC) .

HY-158117

[Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2	Apoptosis Autophagy	Cancer
[Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2 (Compound 3) is a copper complex, which inhibits cell viability of HCT116, HCT116DoxR, A2780 and fibroblasts, with IC₅₀s of 0.13, 0.15, 0.66 and 6.24 μM, respectively. [Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2 induces apoptosis and autophagy, and arrests cell cycle at G0/G1 phase in HCT116DoxR. [Cu2Cl2(4'-(4-Methoxy-1-naphthyl)-terpy)2](PF6)2 exhibits antimetastatic efficacy .

HY-10029A

(Rac)-Nutlin-3 (Rac)-Rebemadlin	MDM-2/p53 Autophagy Apoptosis E1/E2/E3 Enzyme	Cancer
(Rac)-Nutlin-3 (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC₅₀=90 nM). (Rac)-Nutlin-3 inhibits MDM2-p53 interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. (Rac)-Nutlin-3 has the potential for the study of TP53 wild-type ovarian carcinomas .

HY-10226

JNJ-16241199 R306465	Apoptosis HDAC	Cancer
JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC₅₀of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases the expression of p21 ^waf1, ^cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study .

HY-136254

BzATP triethylammonium salt 4 Publications Verification	P2X Receptor	Inflammation/Immunology Cancer
BzATP triethylammonium salt acts as a P2X receptor agonist with pEC₅₀s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively . BzATP triethylammonium salt is potent at P2X7 receptors with EC₅₀s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively .

HY-13776A

XR9051 hydrochloride	P-glycoprotein	Cancer
XR9051 hydrochloride is an orally active and specific modulator of P-glycoprotein-mediated multidrug resistance (MDR) .

HY-13776

XR9051	P-glycoprotein	Cancer
XR9051 is an orally active and specific modulator of P-glycoprotein-mediated multidrug resistance (MDR) .

HY-18745

BzATP triethylammonium Benzoylbenzoyl-ATP triethylammonium	P2X Receptor	Inflammation/Immunology Cancer
BzATP triethylammonium acts as a P2X receptor agonist with pEC₅₀s of 8.74, 5.26, 7.10, 7.50, 6.19, 6.31, 5.33 for P2X1, P2X2, P2X3, P2X2/3, P2X4 and P2X7, respectively . BzATP triethylammonium is potent at P2X7 receptors with EC₅₀s of 3.6 μM and 285 μM for rat P2X7 and mouse P2X7, respectively .

HY-124651

SEMBL	NF-κB MMP	Inflammation/Immunology Cancer
SEMBL is a potent NF-κB inhibitor. SEMBL can inhibit NF-κB-DNA binding, and also inhibits NF-κB-dependent inflammatory cytokine secretions. SEMBL inhibits cancer cell migration and invasion via decreasing MMP expression. SEMBL can be used for researching anticancer .

HY-136174

RBN-2397 5+ Cited Publications	PARP	Cancer
RBN-2397 is a potent, accross species and orally active NAD ⁺ competitive inhibitor of PARP7 (IC₅₀<3 nM). RBN-2397 selectively binds to PARP7 (K_d=0.001 μM) and restores IFN signaling. RBN-2397 has the potential for the study of advanced or metastatic solid tumors .

HY-106662

Chloroquinoxaline sulfonamide Chloroquinoxaline; NSC-339004	Molecular Glues Topoisomerase Parasite	Infection Cancer
Chloroquinoxaline sulfonamide (Chloroquinoxaline), a structural analogue of sulfaquinoxaline, is a topoisomerase II alpha/beta poison. Chloroquinoxaline sulfonamide is used to control coccidiosis in poultry, rabbit, sheep, and cattle . Antitumor activity .

HY-17386R

Rosiglitazone (Standard)	PPAR TRP Channel Autophagy Ferroptosis Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone (Standard) is the analytical standard of Rosiglitazone. This product is intended for research and analytical applications. Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone is an TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-17386

Rosiglitazone Maximum Cited Publications 98 Publications Verification BRL 49653	PPAR TRP Channel Autophagy Ferroptosis Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone is an TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-10626

T0901317 25+ Cited Publications	LXR FXR ROR Apoptosis	Cardiovascular Disease Metabolic Disease Cancer
T0901317 is an orally active and highly selective LXR agonist with an EC₅₀ of 20 nM for LXRα . T0901317 activates FXR with an EC₅₀ of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with K_i values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .

HY-17386A

Rosiglitazone hydrochloride Maximum Cited Publications 98 Publications Verification BRL 49653 hydrochloride	PPAR TRP Channel Autophagy Ferroptosis Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone (BRL 49653) hydrochloride is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone hydrochloride is a TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone hydrochloride can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-17386B

Rosiglitazone potassium BRL 49653 potassium	PPAR TRP Channel Autophagy Apoptosis Ferroptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone (BRL 49653) potassium is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone potassium is a TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone potassium can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-17386S1

Rosiglitazone-d4 BRL 49653-d₄	TRP Channel Autophagy PPAR Ferroptosis Apoptosis Isotope-Labeled Compounds	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Rosiglitazone-d₄ is deuterated labeled Rosiglitazone (HY-17386). Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone is an TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-15995

Tubulysin A 1 Publications Verification TubA	ADC Cytotoxin Antibiotic Microtubule/Tubulin	Cancer
Tubulysin A (TubA) is an anticancer and antiangiogenic agent with anti-microtubule, anti-mitosis and anti-proliferative activity against a variety of cancer cells with IC₅₀ values in the pmol range. It can induce apoptosis of cancer cells and has no effect on normal cells. Tubulysins are a group of potent cytotoxins consisting of nine members (A-I). Tubulysin A can synthesize ADC as ADC Cytotoxin .

Cat. No.	Product Name	Target	Research Area